Q-omics provides the consensus-scored ANKS1B profile across patient tissues and cancer cell-line models. ANKS1B expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, ANKS1B is differentially expressed in 14, with the highest sampling consensus in THCA. Additionally, ANKS1B RNA expression shows 22,049 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight MESO, THCA, and GBM as cancer lineages where ANKS1B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ANKS1B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ANKS1B survival associations across molecular data types. ANKS1B RNA expression shows survival associations in the most cancer types (25), followed by mutation status (10) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ANKS1B RNA expression–survival associations across cancer types. High ANKS1B expression shows unfavorable associations in UCEC, but favorable associations in MESO, PAAD, HNSC, KIRC and CHOL. The MESO Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for ANKS1B RNA expression.
This table summarizes ANKS1B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 1. The strongest signals are observed in THCA for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for ANKS1B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ANKS1B shows lower tumor expression in THCA, HNSC, KICH, BLCA and COAD and higher tumor expression in KIRC. The THCA box plot shows higher ANKS1B RNA expression in normal versus tumor tissue (log2 FC = −2.022, t-test p < 0.001).
This table shows molecular features associated with ANKS1B in patient tissues and cancer cell lines. In patient samples, ANKS1B shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, ANKS1B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in STOMACH and BREAST.
